Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05624385
Other study ID # MRgFUS-Tremor Disorders
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 17, 2023
Est. completion date December 1, 2025

Study information

Verified date April 2023
Source Chinese PLA General Hospital
Contact Yongqin Xiong, MD
Phone +86 18518518771
Email xiongyongqin118@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A study to evaluate the effectiveness and safety of ExAblate transcranial MRgFUS Thalamotomy treatment of medication refractory tremor-related diseases subjects with low skull density ratio (SDR) value. Essential tremor (ET) and Parkinson disease (PD) are the most prevalent tremor disorders. ET, considered as a pure tremor disease, is characterized by upper limb intention or postural tremor, while PD is characterized by a variety of motor and non-motor symptoms, among them rest tremor. A number of studies have demonstrated that Magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy is a minimally invasive and effective procedure suitable for medication-refractory tremor in patients with ET and patients with PD. However, the skull is the main barrier to MRgFUS thalamotomy therapy and patients are screened by calculating SDR value before treatment. The US FDA recommended SDR value >0.45±0.05 as the inclusion criterion for screening patients with tremor treated by MRgFUS system. However, about 20%-50% of patients with SDR value are lower than this standard, which makes this part of patients excluded and unable to accept this treatment with many advantages such as non-invasive, no need for general anesthesia, and no need for hardware implantation. Therefore, this study intended to evaluate the safety and effectiveness of MRgFUS thalamotomy in the treatment of tremor-related patients with low SDR value, so as to provide clinical basis for more patients with tremor to benefit from this treatment.


Description:

Patients: Patients with medication-refractory ET and PD were included. Baseline materials, clinical rating scale for tremor (CRST) , treatment parameters(energy, power, duration time, temperature, target location) , associated adverse effects were recorded. Imaging protocols: T2; T2 Flair; DWI; ESWAN; MRS; 3D ASL 2.0s; 3D-T1; DTI; rs-functional MRI Imaging evaluation: 1. Lesion appearance and volume are measured by T2, T2 Flair, DWI, ESWAN, 3D-T1; 2. ESWAN and MRS manifests the changes of iron deposition and metabolism #respectively; 3. ASL shows regional cerebral blood flow associated with the procedure; 4. DTI demonstrates the destruction of white matter integrity. 5. Rs-functional MRI reflects alterations of resting-state brain activity. Treatment: MRgFUS thalamotomy Follow-up: Baseline (MRI+clinical evaluation); 1-day, 1-month, 3-months, 6-months,1-year, 2-years (MRI+clinical evaluation).


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date December 1, 2025
Est. primary completion date December 1, 2024
Accepts healthy volunteers No
Gender All
Age group 22 Years to 99 Years
Eligibility Inclusion Criteria: 1. Men and women age 22 years or older; 2. Subjects are able and willing to agree to participate in the study and can accept all research visits; 3. A diagnosis of ET and PD as confirmed from clinical history and examination by a neurologist or neurosurgeon specialized in movement disorder and intolerance to side effects of medication or poor response to medication, severe and disabling tremor; 4. Able to adapt to MRI system; 5. To tolerate operation with or without some form of sedative (e.g., awake sedation); 6. Able to communicate with the doctor during the operation; 7. Able to use the "Stop ultrasonic processing" button; 8. Skull density ratio (SDR) = 0.28. Exclusion Criteria: 1. Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, known intolerance or allergies to the MRI contrast agent (e.g.Gadolinium or Magnevist) including advanced kidney disease, etc; 2. Pregnant woman; 3. Subjects with severely impaired renal function; 4. Subjects with unstable cardiac status or severe hypertension (diastolic BP > 100 on medication); 5. Subjects show behaviors consistent with alcohol or drug abuse; 6. History of abnormal bleeding and/or coagulopathy/ or intracranial hemorrhage; 7. Patients who received anticoagulant therapy or medications known to increase the risk of bleeding within the month prior to receiving focused ultrasound treatment; 8. Cerebrovascular disease (multiple CVA or CVA within 3 months); 9. Subjects with brain tumors. 10. Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (can be up to 2 hrs of total time).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MRgFUS treatment
ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Tremor-Related Subjects

Locations

Country Name City State
China Chinese PLA General Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Chinese PLA General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 1.1 Safety To evaluate the incidence and severity of adverse events (AE/AEs) associated with ExAblate Transcranial MRgFUS treatment of subjects during 2-year follow-up. All AE reported by the investigator are classified as: definitely relevant, very likely relevant, probably relevant, probably not relevant or definitely not relevant to the product under study, where definitely relevant, very likely relevant, possibly relevant are classified as relevant, probably not relevant and definitely not relevant are classified as irrelevant. 2 years
Secondary 2.1. Safety To evaluate the incidence and severity of adverse events (AE/AEs) after ExAblate Transcranial MRgFUS treatment of subjects at 24 hours, 1 month, 3 months, 6 months, 12 months, and 2 years follow-up. To evaluate the incidence of unexpected adverse device events (UADE) within 2 years after the treatment of the study product. 2 years
Secondary 2.2. Effectiveness The effectiveness will be evaluated by the hand tremor subscore (on a scale ranging from 0 to 32 when the dominant hand is treated and 0 to 28 points when the nondominant hand is treated, with higher scores indicating more severe tremor), which was derived from the Clinical Rating Scale for Tremor (CRST) . Both the treatment side and the non-treatment side of the subject will be evaluated.
Clinical evaluation will be conducted at the following time points: at screening, at baseline, and 1, 3, 6, 12 months, and 2 years after treatment.
2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05623644 - Multimodal MR Imaging Study on ET and PD Patients Subjected With MRgFUS Thalamotomy
Active, not recruiting NCT03548779 - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 N/A
Completed NCT03295786 - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease Phase 1/Phase 2
Completed NCT03722212 - Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test N/A
Recruiting NCT05973929 - Movement Disorders in Multiple Sclerosis Patients
Terminated NCT02823158 - Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM N/A
Enrolling by invitation NCT01210781 - Target Planning for Placement of DBS-electrodes and Follow-up of the Clinical Efficacy of Stimulation
Enrolling by invitation NCT00355927 - Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders. N/A
Completed NCT00037167 - Effects of Exercise Poles on Older Adults During Exercise Walking Phase 1/Phase 2
Recruiting NCT04784494 - MST for Parkinson's Disease N/A
Terminated NCT03270189 - Effect of the Visual Information Change in Functional Dystonia N/A
Recruiting NCT04176692 - The Effects of Muscle Characteristics on the Control of Shoulder Complex During Functional Movements
Recruiting NCT04061135 - Neurophysiological, Behavioral, and Cognitive Networks in Movement Disorders N/A
Suspended NCT04912115 - Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia Phase 2
Completed NCT00500994 - Neurobiology of Functional Movement Disorder and Non-Epileptic Seizures Early Phase 1
Completed NCT04536987 - Robot Therapy for Rehabilitation of Hand Movement After Stroke Phase 2
Recruiting NCT00001208 - Botulinum Toxin for the Treatment of Involuntary Movement Disorders
Completed NCT02392078 - Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
Completed NCT00552474 - Deep Brain Stimulation to Treat Symptoms of Parkinson's Disease N/A
Not yet recruiting NCT05032911 - Sensorimotor Control in People With and Without Neck Pain